AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03371563 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: Patients were treated with antibiotics for Lyme disease.
Study NCT03371563 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: controls were not given antibiotics
Study NCT03443167 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training on emergency telephone numbers and mnemonics
Description: The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students.
Study NCT03443167 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham generic formation on the cardiopulmonary arrest.
Description: The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102
Description: Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 102
Description: Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mitoxantrone
Description: Administered Q3W for a maximum of 12 cyles
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Administered Q3W for a maximum of 12 cyles
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitoxantrone
Description: Administered Q3W for a maximum of 12 cyles
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: 5 mg orally BID
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally BID
Study NCT00770848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 5 mg orally BID
Study NCT02078479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).
Study NCT02078479 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).
Study NCT01898156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIW-8962
Description: Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops.
Study NCT04474327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Sodium
Description: Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.
Study NCT04689230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper eyelid blepharoplasty
Description: upper eyelid blepharoplasty
Study NCT04689230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: upper eyelid blepharoplasty
Description: upper eyelid blepharoplasty
Study NCT01516983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity.
Study NCT01516983 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy
Description: Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
Study NCT01630733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custirsen
Description: Custirsen: Three loading doses of custirsen 640 mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle
Study NCT01630733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
Study NCT01630733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
Study NCT02903901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 10 mg liquid Melatonin IR-SL at 7 pm for 1 week
Study NCT02903901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg liquid placebo at 7 pm for 1 week
Study NCT04455126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost eye drops
Description: This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
Study NCT00576056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
Study NCT00576056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
Study NCT04314362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 ointment/semi-solid drug
Description: AZR-MD-001 (1.0%) and suitable excipient
Study NCT01231490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01231490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Capsule
Study NCT04540523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming intervention group
Description: In addition to usual daily activity, the parent and child from each family will receive 3 game consoles (Wii, Kinect, and LeapTV) and various exergames (e.g., Nickelodeon Fit, Dance and Sports, Just Dance) with all necessary peripherals to play the games. Specifically, they will receive one game console and related exergames every 2 months to experience the variety of exergames and maintain interest in the games over time. Each parent will receive a booklet (established in our pilots studies) provides a standardized gameplay curriculum to play during each session, and attend training workshops at baseline and 3rd month in the PI's lab. The parent will be instructed to have the child perform exergaming at home for 30 minutes/session, 5 times per week, for 6 months. The games will be age appropriate for children 4-5-years-old. The games have been easy for children to learn and use in our pilot studies.
Study NCT04540523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical activity comparison
Description: Home-based behavioral (e.g., nutrition/PA) interventions for young children usually only target parent for multiple reasons. In this study, group workshop sessions will offered to parents at baseline, 3rd month and 6th month, including information concerning how to promote PA and reduce sedentary behaviors. Identical curricular contents (e.g., dance/sports) for home PA will be offered to parents at baseline and 3rd month in the PI's lab. Parents will also learn about PA and sedentary behavior and their impact on health and cognition. Meanwhile, the intervention staff will encourage parents to increase their lifestyle activity such as taking stairs instead of the elevator and housecleaning. Parents will also learn to shape their child and their PA and sedentary behaviors to attain the following goals: 2 hour or less screen time and at least 180 min. PA per day for children; and at least 150 min. moderate PA for parents per week.
Study NCT01559324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT
Description: Bifrontal ECT, low dosage
Study NCT01559324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT
Description: Right unilateral electrode position, high dosage
Study NCT00800709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
Study NCT03227302 — intervention group
Intervention type: PROCEDURE
Intervention: attending obstetrician
Description: Attending obstetrician can do the caesarean operation without pregnant complications.
Study NCT03227302 — intervention group
Intervention type: PROCEDURE
Intervention: associate obstetrician
Description: Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
Study NCT03227302 — intervention group
Intervention type: PROCEDURE
Intervention: chief obstetrician
Description: Chief obstetrician can do all caesarean operation without limitations.
Study NCT01452022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inductigraft
Description: Synthetic bone graft
Study NCT04786106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)
Description: Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.
Study NCT02429999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrezole plus FSH
Description: letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
Study NCT02429999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol for induction of ovulation
Description: 0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
Study NCT02948361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QT Ultrasound Breast Scan
Description: Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
Study NCT04786106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penile Plication Surgery
Description: Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures \<70 degrees; I\&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I\&G) will ultimately be decided based on the primary investigator's clinical judgment.
Study NCT04786106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Grafting (I&G) Surgery
Description: Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures \<70 degrees; I\&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I\&G) will ultimately be decided based on the primary investigator's clinical judgment.
Study NCT04786106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RestoreX Penile Traction Device
Description: RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.
Study NCT02758691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin
Description: All participants in the devise testing portion of the study will self-administer a 20 IU dose of intranasal insulin. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 IU dose of intranasal insulin.
Study NCT02758691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Saline
Description: All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
Study NCT03241784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous T-regulatory lymphocytes
Description: intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.
Study NCT03241784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.
Study NCT00398112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT00398112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00398112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00585234 — intervention group
Intervention type: OTHER
Intervention: Digital Photography
Description: Digital Photography
Study NCT02103686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Study NCT02103686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: sustained release formulation of pregabalin
Study NCT02103686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat meal
Study NCT02103686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fasted
Study NCT02103686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasted
Study NCT01348230 — intervention group
Intervention type: OTHER
Intervention: Urine samples
Description: collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
Study NCT01383031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CLC
Description: CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
Study NCT01383031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TU-LESSC
Description: TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
Study NCT03724448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleozen
Description: treatment with herbal medicine
Study NCT03724448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: No aleozen treatment
Study NCT01734148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relax To Sleep Program
Description: The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
Study NCT01070329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
Study NCT01070329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
Study NCT00260208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
Study NCT00260208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
Study NCT01504932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BRB Lozenge
Description: ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
Study NCT01504932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
Study NCT01504932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey Administration
Description: Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
Study NCT01504932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
Study NCT01504932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
Study NCT01504932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01504932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Description: Correlative studies
Study NCT04206150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the three different sites of continous adductor canal block: the adductor canal catheter is inserted at femoral triangle apex
Description: In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal).
Study NCT04206150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15*2 cm above the location
Description: In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1.
Study NCT04206150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15 cm below the location
Description: In group 3, the adductor canal catheter is inserted femur length/15 cm below the location where the nerve block performed in group 1.
Study NCT01871883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.